v3.26.1
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) - USD ($)
Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity
Non- Controlling Interest
Total
Balance at Sep. 30, 2024 $ 7,247 $ 271,440,421 $ (201,370,218) $ 70,077,450 $ 4,024,380 $ 74,101,830
Balance (in Shares) at Sep. 30, 2024   7,247,243          
Sale of common stock, net of costs of $425,949 $ 480 2,573,571 2,574,051 2,574,051
Sale of common stock, net of costs of $425,949 (in Shares)   480,000          
Stock-based compensation expense 2,524,824 2,524,824 2,524,824
Net loss (10,281,246) (10,281,246) (10,281,246)
Net loss attributable to non-controlling interest 513,000 513,000 (513,000)
Balance at Dec. 31, 2024 $ 7,727 276,538,816 (211,138,464) 65,408,079 3,511,380 68,919,459
Balance (in Shares) at Dec. 31, 2024   7,727,243          
Balance at Sep. 30, 2024 $ 7,247 271,440,421 (201,370,218) 70,077,450 4,024,380 74,101,830
Balance (in Shares) at Sep. 30, 2024   7,247,243          
Net loss             (30,996,623)
Balance at Jun. 30, 2025 $ 14,475 295,888,916 (230,844,841) 65,058,550 2,502,380 67,560,930
Balance (in Shares) at Jun. 30, 2025   14,475,029          
Balance at Dec. 31, 2024 $ 7,727 276,538,816 (211,138,464) 65,408,079 3,511,380 68,919,459
Balance (in Shares) at Dec. 31, 2024   7,727,243          
Issuance of common stock, net of costs $ 1,034 3,464,773 3,465,807 3,465,807
Issuance of common stock, net of costs (in Shares)   1,033,406          
Stock-based compensation expense 2,702,031 2,702,031 2,702,031
Net loss (11,511,505) (11,511,505)   (11,511,505)
Net loss attributable to non-controlling interest 595,000 595,000 (595,000)
Balance at Mar. 31, 2025 $ 8,761 282,705,620 (222,054,969) 60,659,412 2,916,380 63,575,792
Balance (in Shares) at Mar. 31, 2025   8,760,649          
Issuance of common stock, net of costs $ 2,185 3,292,261 3,294,446 3,294,446
Issuance of common stock, net of costs (in Shares)   2,185,249          
Issuance of common stock and pre-funded warrants in April 2025 registered direct offering, net of costs of $256,116 $ 465 1,743,292 1,743,757 1,743,757
Issuance of common stock and pre-funded warrants in April 2025 registered direct offering, net of costs of $256,116 (in Shares)   465,000          
Issuance of common stock and pre-funded warrants in June 2025 registered direct offering, net of costs of $571,126 $ 540 5,430,296 5,430,836 5,430,836
Issuance of common stock and pre-funded warrants in June 2025 registered direct offering, net of costs of $571,126 (in Shares)   540,000          
Sale of Series A preferred stock 100 100 100 100
Redemption of Series A preferred stock (100) (100) (100) (100)
Issuance of common stock upon exercise of pre-funded warrants $ 2,524 (2,227) 297 297
Issuance of common stock upon exercise of pre-funded warrants (in Shares)   2,524,131          
Stock-based compensation expense 2,719,674 2,719,674 2,719,674
Net loss (9,203,872) (9,203,872) (9,203,872)
Net loss attributable to non-controlling interest       414,000 414,000 (414,000)
Balance at Jun. 30, 2025 $ 14,475 295,888,916 (230,844,841) 65,058,550 2,502,380 67,560,930
Balance (in Shares) at Jun. 30, 2025   14,475,029          
Balance at Sep. 30, 2025 $ 18,068 306,336,239 (238,804,129) 67,550,178 9,977,422 77,527,600
Balance (in Shares) at Sep. 30, 2025   18,067,744          
Issuance of common stock, net of costs $ 252 349,002 349,254 349,254
Issuance of common stock, net of costs (in Shares)   252,137          
October 2025 sale of common stock and pre-funded warrants, net of costs of $75,868 $ 1,460 5,401,471 5,402,931 5,402,931
October 2025 sale of common stock and pre-funded warrants, net of costs of $75,868 (in Shares)   1,460,000          
December 2025 sale of common stock and pre-funded warrants by Citius Oncology, net of costs of $2,872,989 11,258,682 11,258,682 3,866,807 15,125,489
Issuance of common stock upon exercise of pre-funded warrants $ 2,513 (2,262) 251 251
Issuance of common stock upon exercise of pre-funded warrants (in Shares)   2,513,510          
Issuance of common stock for services   $ 83 107,427 107,510 107,510
Issuance of common stock for services (in Shares)   83,036          
Issuance of common stock warrant for note payable extension   68,597 68,597 68,597
Stock-based compensation expense 3,441,544 3,441,544 838,683 4,280,227
Net loss (9,393,889) (9,393,889) (9,393,889)
Net loss attributable to non-controlling interest 1,173,104 1,173,104 (1,173,104)
Balance at Dec. 31, 2025 $ 22,376 326,960,700 (247,024,914) 79,958,162 13,509,808 93,467,970
Balance (in Shares) at Dec. 31, 2025   22,376,427          
Balance at Sep. 30, 2025 $ 18,068 306,336,239 (238,804,129) 67,550,178 9,977,422 77,527,600
Balance (in Shares) at Sep. 30, 2025   18,067,744          
Net loss             (49,422,895)
Balance at Jun. 30, 2026 $ 27,452 343,704,577 (277,118,897) 66,613,132 9,295,324 75,908,456
Balance (in Shares) at Jun. 30, 2026   27,452,570          
Balance at Dec. 31, 2025 $ 22,376 326,960,700 (247,024,914) 79,958,162 13,509,808 93,467,970
Balance (in Shares) at Dec. 31, 2025   22,376,427          
Proceeds from exercise of Citius Oncology pre-funded warrants 818 818 818
December 2025 offering costs (62,764) (62,764) (62,764)
Stock-based compensation expense 2,876,460 2,876,460 911,815 3,788,275
Net loss (28,109,746) (28,109,746) (28,109,746)
Net loss attributable to non-controlling interest 6,878,606 6,878,606 (6,878,606)  
Balance at Mar. 31, 2026 $ 22,376 329,775,214 (268,256,054) 61,541,536 7,543,017 69,084,553
Balance (in Shares) at Mar. 31, 2026   22,376,427          
Issuance of common stock and pre-funded warrants in April 2026 registered direct offering, net of costs of $546,782 $ 4,730 4,448,454 4,453,184 4,453,184
Issuance of common stock and pre-funded warrants in April 2026 registered direct offering, net of costs of $546,782 (in Shares)   4,730,457          
Proceeds from exercise of pre-funded warrants $ 346 (312) 34 34
Proceeds from exercise of pre-funded warrants (in Shares)   345,686          
Citius Oncology net proceeds from exercise of warrants, net of costs of $1,770,000 6,397,475 6,397,475 3,332,525 9,730,000
Citius Oncology warrants issued for loan agreement 492,652 492,652 256,628 749,280
Stock-based compensation expense 2,591,094 2,591,094 1,219,571 3,810,665
Net loss (11,919,260) (11,919,260) (11,919,260)
Net loss attributable to non-controlling interest 3,056,417 3,056,417 (3,056,417)
Balance at Jun. 30, 2026 $ 27,452 $ 343,704,577 $ (277,118,897) $ 66,613,132 $ 9,295,324 $ 75,908,456
Balance (in Shares) at Jun. 30, 2026   27,452,570